Financial protection for patients cannot be achieved through a single intervention: former National Health Authority CEO

You don’t have any Active Subscription.

Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription

Healthcare policy expert Indu Bhushan. File | Photo Credit: The Hindu

Healthcare policy expert and former CEO of the National Health Authority Indu Bhushan, in an exclusive interview with The Hindu, examined whether the National Pharmaceutical Pricing Authority’s (NPPA) recent decision to cap trade margins on 137 anti-cancer medicines will translate into meaningful savings for patients.

Drawing on his experience implementing the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), he highlights the need for pricing transparency, regulatory oversight and sustainable healthcare financing.

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.